MSD France and Lille University Regional Hospital Centre supported by Inserm Transfert sign a partnership agreement on the FREGAT Clinical-Biological database to improve the management of patients suffering from oesophago-gastric cancers.
Paris, 24 January 2017 – FREGAT (FRench Esophageal and GAastric Tumors) is the reference clinical and biological database for oesophago-gastric cancers in France. It already contains more than 1350 people listed in the database. The project intends to include 500 additional patients per year and monitor them throughout their disease. The aim of this cohort is to conduct a prospective collection of clinical, biological, tumour, quality of life and human and social sciences data together with blood and tumour samples. Its objective is to carry out research into the causes of treatment resistance to improve understanding about these patients care pathway and develop new treatments.
Lille Regional University Hospital, supported in its work by Inserm Transfert, has just signed a 4 year partnership agreement with the MSD France Company for the FREGAT cohort. During this period MSD France will carry out research projects based on the FREGAT body of data and samples.